Tarsus Pharmaceuticals Inc. has a shot at reaching blockbuster sales with the US Food and Drug Administration approval of Xdemvy (lotilaner) for Demodex blepharitis, given the high prevalence of the condition – an eyelid disease that results from mite infestation – and the efficacy the drug demonstrated in pivotal trials.
Tarsus Targets Initial Small Segment Of Blepharitis Population With Xdemvy Approval
The company plans to focus on 7 million of the 25 million potentially addressable Demodex blepharitis patients at first, but even that could yield blockbuster sales over the next decade.
More from New Products
More from Scrip
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.